At a glance
ClinicalIndex Comparison RecordN/ACompleted· 146 enrolled
Drug / intervention
ReSTORdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Surgeon Experience ReSTOR Aspheric +4 Intraocular Lens (IOL)
In Brief
An observational study evaluating ReSTOR for Cataract. Completed, enrolled 146 participants across 1 site.
Detailed Summary
To collect visual outcome data post AcrySof ReSTOR Aspheric +4 implantation from surgeons throughout the United States.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCataract
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2007
Primary CompletionMar 2008
First PostedAug 2008
TodayJul 2026
First PostedAug 13, 2008
Enrollment StartJun 1, 2007
Primary CompletionMar 1, 2008
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 17.9 years ago
Interventions
ReSTORdevice
Patients were implanted with the AcrySof ReSTOR Aspheric +4 Intraocular Lens (IOL) in one or both eyes for treatment of cataract.